Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.

Erythropoietin refractory anemias represent a continuing and increasing burden on the healthcare system. The current practice of providing these patients with rHuEPO does not seem to be working. Fewer than 50% of patients respond in some studies. We demonstrate that androgens have multiple benefits in this population. They control anemia and stop transfusion dependence and improve nutritional parameters. In some patients, they also have a salutary effect on both white blood cell and platelet counts.
AuthorsBobby Chawla, Fahad M Iqbal, Manjeet S Chawla
JournalComprehensive therapy (Compr Ther) 2009 Fall-Winter Vol. 35 Issue 3-4 Pg. 199-203 ISSN: 0098-8243 [Print] United States
PMID20043618 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Androgens
  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Nandrolone
  • nandrolone decanoate
  • Aged
  • Androgens (administration & dosage, therapeutic use)
  • Anemia (drug therapy, etiology)
  • Blood Cell Count
  • Blood Transfusion
  • Drug Resistance
  • Erythropoietin (therapeutic use)
  • Female
  • Hematinics (therapeutic use)
  • Hemoglobins (analysis)
  • Humans
  • Middle Aged
  • Nandrolone (administration & dosage, analogs & derivatives, therapeutic use)
  • Neoplasms (complications)
  • Recombinant Proteins
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: